Patent US4432752A successfully refreshed from Google Patents.
Patent US2318168A successfully refreshed from Google Patents.
EP0203587A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Ras oncogene peptides and antibodies
Assignee: F Hoffmann La Roche AG
•
Filing: 1986-05-28
•
Granted: —
•
Expires: 2006-05-28
Abstract
Abstract Novel ras oncogene polypeptides derived from the C-terminal variable region of different members of the p21ras protein family as well as monoclonal and polyclonal antibodies specific to such region are described. Such antibodies are useful for immunometric assays for the determination of the presence of each individual member of the p21 ras onco- gen protein family or combination thereof.
Inventors
- 👤 Richard A. Chizzonite
- 👤 Arthur M. Felix
- 👤 Mark E. Furth
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-28 12:20
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/82; C07K16/00; C07K16/18; C07K16/32; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/57575
Claims Analysis
Total Claims: 40
Claim 1
Independent Claim
12 words
A polypeptide selected from the group consisting of: and of derivatives thereof.
Claim 2
Dependent Claim
12 words
A polypeptide selected from the group consisting of: and of derivatives thereof.
Claim 3
Dependent Claim
29 words
A polypeptide derivative comprising a compound of claim 1 in side-chain and N-terminal protected form with the carboxyl terminal being covalently linked to a polystyrene solid phase synthesis resin.
Claim 4
Dependent Claim
35 words
An immunogenic composition suitable for eliciting formation of antibodies specific for a p21ras polypeptide or protein in a host, said immunogenic composition comprising a polypeptide of claim 1 covalently bound to an immunogenic carrier material.
Claim 5
Dependent Claim
22 words
An antibody selective for human p21ras H polypeptide and non-crossreactive with human p 21ras N , p21ras K4A and p21ras K4B polypeptides.
Claim 6
Dependent Claim
22 words
An antibody selective for human p21ras H polypeptide and non-crossreactive with human p 21ras N , p21ras K4A and p21ras K4B polypeptides.
Claim 7
Dependent Claim
23 words
The antibody of claim 4 elicited with an immunogenic composition according to claim 3 said immunogenic composition comprising a polypeptide having the sequence:
Claim 8
Dependent Claim
23 words
The antibody of claim 4 elicited with an immunogenic composition according to claim 3 said immunogenic composition comprising a polypeptide having the sequence:
Claim 9
Dependent Claim
21 words
An antibody selective for human p2lras N polypeptide and non-crossreactive with human p21ras H , p21ras K4A and p21ras K4B polypeptides.
Claim 10
Dependent Claim
21 words
An antibody selective for human p2lras N polypeptide and non-crossreactive with human p21ras H , p21ras K4A and p21ras K4B polypeptides.
Claim 11
Dependent Claim
23 words
The antibody of claim 7 elicited with an immunogenic composition according to claim 3 said immunogenic composition comprising a polypeptide having the sequence:
Claim 12
Dependent Claim
20 words
An antibody selective for human p21ras K4A polypeptide and non-crossreactive with human p21ras , p21ras N and p21ras K4B polypeptides.
Claim 13
Dependent Claim
20 words
An antibody selective for human p21ras K4A polypeptide and non-crossreactive with human p21ras , p21ras N and p21ras K4B polypeptides.
Claim 14
Dependent Claim
23 words
The antibody of claim 9 elicited with an immunogenic composition according to claim 3 said immunogenic composition comprising a polypeptide having the sequence:
Claim 15
Dependent Claim
20 words
An antibody selective for human p21ras K4B polypeptide and non-crossreactive with human p21ras , p21ras N and p21ras K4A polypeptides.
Claim 16
Dependent Claim
20 words
An antibody selective for human p21ras K4B polypeptide and non-crossreactive with human p21ras , p21ras N and p21ras K4A polypeptides.
Claim 17
Dependent Claim
27 words
The antibody of claim 11 elicited with an immunogenic composition according to claim 3 wherein said immunogenic composition comprising a polypeptide having the sequence: H 2 N-Met-Ser-Lys-Asp-Gly-Lys-Lys-Lys-Lys-Lys-
Claim 18
Dependent Claim
16 words
An antibody according to any one of claims 4 to 12 which is a monoclonal antibody.
Claim 19
Dependent Claim
21 words
A process for the preparation of a polypeptide according to claim 1 characterized in that conventional polypeptide synthesis methods are used.
Claim 20
Dependent Claim
15 words
A process according to claim 14 characterized in that solid phase synthesis methods are used.
Claim 21
Dependent Claim
30 words
A process for the preparation of an immunogenic composition according to claim 3 characterized in that a polypeptide of claim 1 is directly covalently coupled to an immunogenic carrier material.
Claim 22
Dependent Claim
34 words
A process for the preparation of an immunogenic composition according to claim 3 characterized in that a polypeptide of claim 1 is coupled to an immunogenic carrier material via a conventional bifunctional linking group.
Claim 23
Dependent Claim
47 words
A process for the preparation of an antibody as claimed in any one of claims 4 to 12 characterized in that an immunogenic composition according to claim 3 is injected into a host, capable of eliciting an immune response against the ras polypeptide of the immunogenic composition.
Claim 24
Dependent Claim
57 words
An immunometric assay for a combination of two or more human p21ras proteins selected from the group consisting of p21ras H , p21ras N , p21ras K4A and p21ras K4B in a test sample characterized in employing antibodies selective for the human p21ras proteins to be assayed, said antibodies being non-crossreactive with the other human p21ras proteins.
Claim 25
Dependent Claim
57 words
An immunometric assay for a combination of two or more human p21ras proteins selected from the group consisting of p21ras H , p21ras N , p21ras K4A and p21ras K4B in a test sample characterized in employing antibodies selective for the human p21ras proteins to be assayed, said antibodies being non-crossreactive with the other human p21ras proteins.
Claim 26
Dependent Claim
54 words
2 0 . An immunometric assay for a human p21ras protein selected from the group consisting of p21ras H , p2lrasN p21ras K4A and p21ras K4B in a test sample characterized in employing an antibody selective for the human p21ras protein to be assayed, said antibody being non-crossreactive with the other human p21ras proteins.
Claim 27
Dependent Claim
54 words
2 0 . An immunometric assay for a human p21ras protein selected from the group consisting of p21ras H , p2lrasN p21ras K4A and p21ras K4B in a test sample characterized in employing an antibody selective for the human p21ras protein to be assayed, said antibody being non-crossreactive with the other human p21ras proteins.
Claim 28
Dependent Claim
12 words
An immunometric assay according to claim 20 which is a heterogeneous assay.
Claim 29
Dependent Claim
49 words
An immunometric assay according to claim 21 wherein an immunoblot procedure is employed, wherein the presence of an immune complex formed between a human p21ras protein to be assayed in the test sample and a selective antibody is determined by contacting said immune complex with a labelled second antibody.
Claim 30
Dependent Claim
38 words
An immunometric assay according to claim 22 wherein the second antibody is labelled with an enzyme and a substrate for such enzyme is added, said substrate being converted by said enzyme from a non-colored to a colored state.
Claim 31
Dependent Claim
12 words
An immunometric assay according to claim 20 which is a homogeneous assay.
Claim 32
Dependent Claim
37 words
An immunometric assay according to claim 24 which is a competitive inhibition assay utilizing a known amount of a labelled human p21ras protein or carboxy terminal fragment thereof corresponding to the human p21ras protein to be assayed.
Claim 33
Dependent Claim
69 words
A process for the purification of a specific human p21ras protein selected from the group consisting of p21ras H , p21ras N , p21ras K4A and p21ras K4B c h aract e - rized in that the purification is done using an antibody selective for the human p21ras protein to be purified and non-crossreactive to other members of the human p21ras protein family bound to an affinity chromatography matrix.
Claim 34
Dependent Claim
69 words
A process for the purification of a specific human p21ras protein selected from the group consisting of p21ras H , p21ras N , p21ras K4A and p21ras K4B c h aract e - rized in that the purification is done using an antibody selective for the human p21ras protein to be purified and non-crossreactive to other members of the human p21ras protein family bound to an affinity chromatography matrix.
Claim 35
Dependent Claim
18 words
27 Use of an immunogenic composition according to claim 3 for eliciting an immune response in a host.
Claim 36
Dependent Claim
17 words
Use of an antibody according to any one of claims 4 to 13 for an immunometric assay.
Claim 37
Dependent Claim
32 words
Use of an antibody according to any one of claims 4 to 13 for the purification of a human p21ras protein or polypeptide comprising an amino acid sequence according to claim 1.
Claim 38
Dependent Claim
32 words
Use of an immunometric assay according to any one of claims 19 to 25 for assaying a specific human p21ras protein or polypeptide comprising an amino acid sequence according to claim 1.
Claim 39
Dependent Claim
15 words
Immunogenic composition according to claim 3 suitable for eliciting an immune response in a host.
Claim 40
Dependent Claim
22 words
Antibody according to any one of claims 4 to 13 suitable for use in an immunometric assay for a human p21ras protein.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.